HAEMONETICS CORPHAEEarnings & Financial Report
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Revenue
$330.6M
Gross Profit
$193.1M
Operating Profit
$71.3M
Net Profit
$58.0M
Gross Margin
58.4%
Operating Margin
21.6%
Net Margin
17.5%
YoY Growth
N/A
EPS
$1.17
HAEMONETICS CORP Q4 FY2025 Financial Summary
HAEMONETICS CORP reported revenue of $330.6M for Q4 FY2025, with a net profit of $58.0M (17.5% margin). Cost of goods sold was $137.5M, operating expenses totaled $121.7M.
Key Financial Metrics
| Total Revenue | $330.6M |
|---|---|
| Net Profit | $58.0M |
| Gross Margin | 58.4% |
| Operating Margin | 21.6% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
HAEMONETICS CORP Q4 FY2025 revenue of $330.6M breaks down across 5 segments, led by Hospital at $147.2M (44.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Hospital | $147.2M | 44.5% |
| Hospital Productsand Services | $66.8M | 20.2% |
| Blood Center | $54.8M | 16.6% |
| Blood Center Productsand Services | $54.3M | 16.4% |
| Other | $7.5M | 2.3% |
HAEMONETICS CORP Revenue by Segment — Quarterly Trend
HAEMONETICS CORP revenue by segment across the last 4 reported quarters, showing how each business line (such as Hospital and Hospital Productsand Services) has evolved quarter over quarter.
| Segment | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 |
|---|---|---|---|---|
| Hospital | $143.5M | $145.5M | $139.7M | $147.2M |
| Hospital Productsand Services | — | $59.1M | — | $66.8M |
| Blood Center | — | — | — | $54.8M |
| Blood Center Productsand Services | $56.6M | — | $51.8M | $54.3M |
| Other | — | — | — | $7.5M |
HAEMONETICS CORP Annual Revenue by Year
HAEMONETICS CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.4B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.4B |
| 2022 | $993.2M |
HAEMONETICS CORP Quarterly Revenue & Net Profit History
HAEMONETICS CORP results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2026 | $339.0M | -2.7% | $44.7M | 13.2% |
| Q2 FY2026 | $327.3M | -5.3% | $38.7M | 11.8% |
| Q1 FY2026 | $321.4M | -4.4% | $34.0M | 10.6% |
| Q4 FY2025 | $330.6M | — | $58.0M | 17.5% |
| Q3 FY2025 | $348.5M | +3.7% | $37.5M | 10.8% |
| Q2 FY2025 | $345.5M | +8.6% | $33.8M | 9.8% |
| Q1 FY2025 | $336.2M | — | $38.4M | 11.4% |
| Q3 FY2024 | $336.3M | +10.1% | $31.2M | 9.3% |
Income Statement
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $336.3M | $336.2M | $345.5M | $348.5M | $330.6M | $321.4M | $327.3M | $339.0M |
| YoY Growth | 10.1% | N/A | 8.6% | 3.7% | N/A | -4.4% | -5.3% | -2.7% |
Balance Sheet
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.20B | $2.54B | $2.53B | $2.53B | $2.45B | $2.46B | $2.44B | $2.49B |
| Liabilities | $1.26B | $1.64B | $1.65B | $1.62B | $1.63B | N/A | N/A | N/A |
| Equity | $943.3M | $905.4M | $878.9M | $906.9M | $820.8M | $882.3M | $849.2M | $911.5M |
Cash Flow
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-540000 | $-27.4M | $48.8M | $43.8M | $116.6M | $17.4M | $111.3M | $93.6M |